• Pharmacokinetics and Safety of Gepotidacin: Phase I Insights

  2026-06-19

  This article reviews key findings from a phase I clinical study evaluating the pharmacokinetics, safety, and tolerability of gepotidacin (GSK2140944), a novel triazaacenaphthylene antibiotic. These results inform future antibacterial research, especially for addressing multidrug-resistant infections.

• Recombinant Mouse IFN-γ: Precision in Immunomodulatory Assay

  2026-06-19

  Recombinant Mouse IFN-γ (E.coli, His & Strep, Liquid) delivers robust, reproducible modulation of immune cell function in advanced antigenicity and macrophage activation workflows. Cited research reveals how this cytokine can restore tumor immune surveillance, especially in bile acid–driven MASH-HCC models, enabling translational labs to bridge mechanistic insights with actionable experimental protocols.

• BMS 599626 Dihydrochloride: Selective EGFR/ErbB2 Inhibitor P

  2026-06-18

  BMS 599626 dihydrochloride is a potent, selective EGFR and ErbB2 inhibitor used to block tumor cell proliferation and receptor phosphorylation. Its precise action enables robust cancer cell signaling studies and xenograft tumor growth suppression. This article details its mechanism, evidence, and optimal research use.

• Flumequine: Potent DNA Topoisomerase II Inhibitor for Resear

  2026-06-18

  Flumequine is a synthetic chemotherapeutic antibiotic widely used as a DNA topoisomerase II inhibitor in DNA replication and cancer research. It exhibits a robust IC50 of ~15 μM in enzyme inhibition assays and features well-defined physicochemical properties, supporting reproducible, quantitative studies.

• NSAID Cytotoxicity in Canine Osteosarcoma: Viability and Apo

  2026-06-17

  This study assessed the cytotoxic effects of deracoxib and piroxicam on canine osteosarcoma cells, revealing that deracoxib more potently inhibited cell viability than piroxicam, without inducing apoptosis. The findings inform the nuanced application of NSAIDs as antiproliferative agents in tumor cell line research and highlight key limitations for translational relevance.

• Nebivolol Hydrochloride: Precision β1-Adrenoceptor Antagonis

  2026-06-17

  Nebivolol hydrochloride enables highly selective manipulation of β1-adrenergic signaling in cardiovascular and hypertension research. This guide translates breakthrough discovery science—including recent mTOR selectivity validation—into actionable protocols, advanced use-cases, and troubleshooting strategies for reproducible, pathway-specific experimentation.

• Scenario-Driven Solutions for Apoptosis Assays with Boc-D-FM

  2026-06-16

  This article provides laboratory scientists with a scenario-based guide to tackling common cell viability and apoptosis assay challenges using Boc-D-FMK (SKU A1904). Drawing on validated experimental data, it details best practices for protocol optimization, data interpretation, and product selection, with workflow recommendations grounded in APExBIO’s trusted pan-caspase inhibitor.

• Gepotidacin: Mechanistic Innovation for Translational Antibi

  2026-06-16

  This article provides strategic guidance for translational researchers by dissecting the unique mechanism of Gepotidacin (GSK2140944) as a first-in-class bacterial DNA gyrase and topoisomerase IV inhibitor. Integrating recent mechanistic studies, competitive landscape analysis, and protocol recommendations, it offers advanced insights and actionable parameters for antibacterial research targeting resistant pathogens. The discussion highlights how Gepotidacin's non-fluoroquinolone scaffold overcomes key resistance barriers, setting a new standard for rational antibiotic development and experimental design.

• Mechanistic Insights and LNP Integration with EZ Cap™ Firefl

  2026-06-15

  Explore the advanced design of EZ Cap™ Firefly Luciferase mRNA (5-moUTP) for superior gene expression studies. This article provides unique mechanistic analysis and practical integration with LNP delivery, offering strategic depth beyond standard bioluminescent reporter workflows.

• LY364947: TGF-β Type I Receptor Kinase Inhibitor in EMT Rese

  2026-06-15

  LY364947 stands out as a highly selective TGF-β type I receptor kinase inhibitor that empowers researchers to dissect and modulate EMT and fibrosis with precision. Its robust solubility profile and workflow compatibility, combined with evidence-backed performance in both in vitro and in vivo models, position it as a gold-standard tool for translational research.

• Cyclophilin A Defines Cyclosporine’s Mechanism in Immunosupp

  2026-06-14

  This paper demonstrates that cyclophilin A is essential for cyclosporine’s immunosuppressive effect, as mice lacking cyclophilin A remain resistant to the drug. The findings pinpoint cyclophilin A as the primary intracellular target of cyclosporine, refining our understanding of calcineurin inhibitor specificity in transplantation and autoimmune research.

• BMS 599626 Dihydrochloride: Precision Tools for EGFR/ErbB2 R

  2026-06-13

  Explore how BMS 599626 dihydrochloride—a potent EGFR and ErbB2 inhibitor—enables advanced, multiparametric cancer and senescence research. This article uniquely bridges molecular mechanism, AI-driven drug discovery, and practical assay optimization.

• Bafilomycin A1: Deconstructing V-ATPase Inhibition in Autoph

  2026-06-12

  Explore the advanced role of Bafilomycin A1 as a V-ATPase inhibitor in dissecting autophagic flux, lysosomal function, and host-pathogen dynamics. This article delivers unique insights grounded in recent immunological research, bridging fundamental mechanisms with practical assay design.

• Ibrexafungerp (MK 3118): Protocols for Antifungal Research S

  2026-06-12

  Ibrexafungerp stands apart as an oral triterpenoid antifungal, maintaining potent activity against multidrug-resistant and azole-resistant Candida in acidic environments—vital for vulvovaginal candidiasis research. This article delivers actionable workflows, troubleshooting, and comparative perspectives to maximize experimental power with this APExBIO-supplied compound.

• Dextran Microgels for Oral Colon Cancer Therapy: Targeted De

  2026-06-11

  This study introduces a dual-targeted dextran microgel system encapsulating cisplatin and SPION-loaded lipid nanoparticles for effective, localized colorectal cancer therapy via oral administration. The approach demonstrates improved colon-specific drug delivery, enhanced cellular uptake, and significant inhibition of tumor growth and metastasis in preclinical models.

451 records 14/31 page Previous Next First page 上5页 1112131415 下5页 Last page